Technology Leadership

Can AI achieve true consciousness? A psychologist, Buddhist scholar, and AI designer examine why Buddhism offers the most robust framework for understanding mind—and why quantum physics suggests consciousness extends beyond the brain.

Remote work and artificial intelligence are dissolving the permanent team, replacing it with fluid, project-based "flash teams" that assemble and dissolve in weeks. This shift carries a hidden psychological toll: eroded trust, loneliness, and a weak psychological contract between employees and organisations.

Forget chalky shakes. Asia’s food technologists are bottling clarity and crystallising fibre. Our correspondent examines the continent’s quiet revolution in satiety science—and what it means for global portfolios.

Discover why collective triumph outperforms personal ambition in business. Drawing on Harvard-level management research and ancient Confucian & Daoist philosophy, this article reveals how collaborative cultures drive 34% higher quality and deeper professional satisfaction. A must-read for leaders rethinking incentive systems.

Why food science graduates need business skills to succeed in B2B ingredient markets. A Kingfisher Associates analysis of curriculum reform, faculty recruitment, and Singapore's talent gap.

The Nostalgia Economy is now worth hundreds of billions globally—and Gen Z is leading the charge. But unlike older generations, Gen Z isn't buying history; they're buying escape. From Y2K aesthetics to analog tech, they're drawn to eras that feel simpler, slower, and more grounded than today's digital-saturated world. This blog explores why "fauxstalgia" is reshaping consumer behavior and how your brand can authentically tap into this trend without alienating your core audien

Can AI protect our most sensitive data? Explore the privacy challenges of AI-driven genomics and how federated learning, encryption & synthetic data are securing the future.

Cell and gene therapy (CGT) has entered a new era. The FDA approved seven new cell and gene therapies in 2024–2025, including Abeona’s ZEVASKYN and Novartis’s ITVISMA. These curative treatments are no longer science fiction – they are reaching patients. But here is the problem that smart investors are watching closely: manufacturing is failing.